Publicacións nas que colabora con José Domingo Pedreira Andrade (29)

2020

  1. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  2. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

2017

  1. Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients

    Journal of Clinical Virology, Vol. 88, pp. 58-61

  2. Tendencia de las hospitalizaciones, reingresos y mortalidad intrahospitalaria en los pacientes infectados por VIH entre 1993-2013: impacto de la coinfección por el virus de la hepatitis C

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 35, Núm. 1, pp. 20-26

  3. Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: Impact for monitoring and optimizing treatment duration

    European Journal of Gastroenterology and Hepatology, Vol. 29, Núm. 7, pp. 781-785

2016

  1. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 4, pp. 1051-1055

  2. European mitochondrial haplogroups impact on liver fibrosis progression among HCV and HIV/HCV-coinfected patients from Northwest Spain

    Journal of Acquired Immune Deficiency Syndromes, Vol. 73, Núm. 2, pp. 149-153

  3. Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain

    Journal of Medical Virology, Vol. 88, Núm. 12, pp. 2125-2131

2015

  1. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792

  2. Lung cancer in patients living with HIV infection

    AIDS

  3. Molecular characterization of HIV-1 infection in Northwest Spain (2009-2013): Investigation of the subtype F outbreak

    Infection, Genetics and Evolution, Vol. 30, pp. 96-101

  4. Trends on epidemiological, virological, and clinical features among newly diagnosed HIV-1 persons in Northwest Spain over the last 10 years

    Journal of Medical Virology, Vol. 87, Núm. 8, pp. 1319-1326

2014

  1. High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment response

    AIDS, Vol. 28, Núm. 12, pp. 1837-1840

  2. Highlights from CROI 2014 on experimental HIV drugs

    AIDS Reviews

  3. Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers

    Journal of Gastroenterology and Hepatology (Australia), Vol. 29, Núm. 1, pp. 173-178

  4. Seroprevalence of HCV and HIV infections by year of birth in Spain: Impact of US CDC and USPSTF recommendations for HCV and HIV testing

    PLoS ONE, Vol. 9, Núm. 12

2013

  1. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B

    AIDS, Vol. 27, Núm. 14, pp. 2219-2224

  2. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9